Cancer Archives

News and Trends 13 Apr 2023

Alentis Therapeutics raises $105M for claudin platform

Alentis Therapeutics is a clinical-stage biotech developing treatments for organ fibrosis and claudin-1 (CLDN1) positive tumors. The company has announced $105 million in Series C financing. The funding round was led by Jeito Capital, Novo Holdings A/S and RA Capital Management with participation from existing investors including BB Pureos Bioventures, Bpifrance through its InnoBio 2 […]

April 13, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 11 Apr 2023

Sumitomo Pharma Oncology receives orphan drug designation for Ewing sarcoma treatment

Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, said the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for TP-1287, an investigational oral CDK9 inhibitor, for the treatment of Ewing sarcoma. “We are delighted to have received this designation for TP-1287 which underscores the need for additional treatment […]

April 11, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 11 Apr 2023

Intracellular drug delivery startup Vitarka Therapeutics raises £1.27M

Vitarka Therapeutics, which focuses on non-viral drug delivery technology, has raised £1.27 million ($1.58 million) in equity from venture capital firm SOSV, the UK Innovation & Science Seed Fund (UK12S) and grant funding from Innovate UK. Founded in 2021 by Vineeta Tripathi, Vitarka Therapeutics is developing combination medicines using RNAi therapies and a non-viral drug […]

April 11, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 5 Apr 2023

Mosaic Therapeutics closes $28M series A funding

Mosaic Therapeutics, Ltd has closed its $28 million series A funding round. The investment in this round was raised from Syncona Investment Management, Ltd, and Cambridge Innovation Capital. The company also announced the appointment of former Novartis Oncology SVP Brian Gladsden as CEO. The Series A funding will be used to further advance Mosaic Therapeutics’ pipeline […]

April 5, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 4 Apr 2023

BioNTech adds antibody-drug conjugates to cancer portfolio with potential $1.5B partnership deal

BioNTech SE and Duality Biologics (Suzhou) Co. Ltd. have entered into exclusive license and collaboration agreements for two antibody-drug conjugate (ADC) assets to develop, manufacture and commercialize the two assets globally, excluding mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region. With this collaboration, ADCs will become an additional drug class in […]

April 4, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 4 Apr 2023

iNtRON looks to control colorectal cancer through microbiome

iNtRON Biotechnology has announced that it has demonstrated the effectiveness of P18-BE3CRC using a cancer organoid model. P18-BE3CRC is a drug candidate from iNtRON Biotechnology’s PHAGERIA platform technology, which is for the development and commercialization of bacteriophage-based drugs (Phageome API) for cancer control. Bacteriophages have been used for R&D on bacterial infectious diseases, but recently […]

April 4, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 4 Apr 2023

Discovery could lead to cancer drugs with fewer side effects

Many anticancer drugs have serious side-effects in clinical practice. Kinesin inhibitors block kinesin motor proteins required for cancer cell division, and are promising anticancer drug candidates with minimal side-effects. However, their association with kinesin proteins remains unclear. Researchers from Japan have addressed this by solving the crystal structure of the complex formed by the kinesin […]

April 4, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 31 Mar 2023

Ablaze Pharmaceuticals to develop first-in-class therapy for liver cancer in China

Ablaze Pharmaceuticals, a biotech company focused on developing targeted radiotherapy (TRT) to benefit cancer patients in China, is developing plans for a first-in-class novel peptide drug candidate against GPC3. The proprietary GPC3-targeting peptide is being licensed from RayzeBio. Upon in-license of product candidates by Ablaze from RayzeBio, Ablaze will be responsible for clinical development and […]

March 31, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 31 Mar 2023

Candidate found to inhibit malignant melanoma growth

Malignant melanoma is a relatively aggressive type of skin cancer. When detected early, it is usually treatable by surgical resection only, but metastases develop, often spreading to distant areas. Currently, tumor thickness and the presence of ulceration are some of the known prognostic factors used as indicators of melanoma. Therefore, the discovery of markers to […]

March 31, 2023 - 2 minutesmins - By Jim Cornall

Podcast 31 Mar 2023

Beyond Biotech podcast 40: Antibody-drug conjugates

This episode of the podcast is an in-depth look at antibody drug conjugates (ADCs). Our guests are Dr Pini Tsukerman, chief scientific of Nectin Therapeutics, and Matthew Robinson, chief technology officer of Immunome. This episode of the podcast is sponsored by PHTA. Immunome Immunome’s Discovery Engine leverages the information stored in memory B cells to […]

March 31, 2023

News and Trends 30 Mar 2023

Vaccitech announces positive topline data for chronic hepatitis study

Vaccitech plc has announced positive topline final data from the HBV002 study, a phase 1b/2a clinical trial of VTP-300 in people with chronic hepatitis B (HBV) infection. Vaccitech is a clinical-stage biopharmaceutical company focused on the development of novel T cell immunotherapeutics to use the immune system to potentially treat and cure chronic infectious diseases, […]

March 30, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 24 Mar 2023

Metabolism of RNA linked to leukemia

Researchers at Lund University Faculty of Medicine in Sweden have determined a novel mechanism linking the metabolism of ribonucleic acids, RNA, to the development of leukemia in myelodysplastic syndrome patients, MDS. In a study published in the Molecular Cell journal, they explain what makes hematopoietic stem cells acquire malignant traits in cancer. RNA splicing is […]

March 24, 2023 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Alentis Therapeutics raises $105M for claudin platform

Sumitomo Pharma Oncology receives orphan drug designation for Ewing sarcoma treatment

Intracellular drug delivery startup Vitarka Therapeutics raises £1.27M

Mosaic Therapeutics closes $28M series A funding

BioNTech adds antibody-drug conjugates to cancer portfolio with potential $1.5B partnership deal

iNtRON looks to control colorectal cancer through microbiome

Discovery could lead to cancer drugs with fewer side effects

Ablaze Pharmaceuticals to develop first-in-class therapy for liver cancer in China

Candidate found to inhibit malignant melanoma growth

Beyond Biotech podcast 40: Antibody-drug conjugates

Vaccitech announces positive topline data for chronic hepatitis study

Metabolism of RNA linked to leukemia

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!